PMID- 35508863 OWN - NLM STAT- MEDLINE DCOM- 20221003 LR - 20221207 IS - 1993-0402 (Electronic) IS - 1672-0415 (Print) IS - 1672-0415 (Linking) VI - 28 IP - 10 DP - 2022 Oct TI - Effectiveness and Safety of Baidu Jieduan Granules for COVID-19: A Retrospective Observational Multicenter Study. PG - 885-893 LID - 10.1007/s11655-022-3673-x [doi] AB - OBJECTIVE: To evaluate the effectiveness and safety of Baidu Jieduan Granules (BDJDG) to treat common type coronavirus disease 2019 (COVID-19). METHODS: This multicenter, retrospective, and observational clinical trial included 230 common COVID-19 patients in Leishenshan, Huangshi, and Laohekou Hospitals in Wuhan from January 21 to March 26, 2020. The included patients were further divided into two subgroups according to the use of supplemental oxygen, mild and moderate groups. During the first 14 d of hospitalization, all patients were administered BDJDG combined with conventional Western medicine, and observed for continuous 28 d. Primary outcomes were disease progression rate and discharge rate. Secondary outcomes included negative conversion time of nucleic acid, hospitalization duration, clinical symptom subsidence time, and symptom regression rate. RESULTS: A total of 230 common COVID-19 patients were analyzed (138 in moderate group and 92 in mild group). By day 28, the disease progression rate was 4.3% and the discharge rate was 95.7%. All mild cases recovered and were discharged from hospital. The median negative conversion time of nucleic acid of all 230 COVID-19 patients was 12 d [inter-quartile range (IQR) 3.5-17], the median hospitalization duration was 15 d (IQR 12-20). The median time to fever, cough, and fatigue recovery was 4 d (IQR 2-6), 8 d (IQR 5-12), and 8 d (IQR 5-11). The recovery rate of fever, cough, and fatigue was 94.6%, 90.5%, and 93.5%. The median time to clinical improvement was 12 d (IQR 10-17). Compared with the baseline, total leukocyte counts, neutrophil counts, lymphocyte counts, and platelet counts were increased significantly on days 7 and 14 (P<0.01). C-reactive protein markedly increased on day 3 and significantly decreased on days 7 and 14 (P<0.01). No serious adverse events occurred during treatment. CONCLUSION: BDJDG may be effective and safe for treatment of common type COVID-19. (Registration No. ChiCTR2000030836). CI - (c) 2022. The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Xu, Xiang-Ru AU - Xu XR AD - Department of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China. FAU - Zhang, Wen AU - Zhang W AD - Department of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China. FAU - Wu, Xin-Xin AU - Wu XX AD - Department of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China. FAU - Huang, Ting-Rong AU - Huang TR AD - Department of Emergency, Huangshi Hospital of Traditional Chinese Medicine (Infectious Disease Hospital), Huangshi, Hubei Province, 435004, China. FAU - Zuo, Jian-Guo AU - Zuo JG AD - Department of Emergency, The First Hospital of Laohekou, Laohekou, Hubei Province, 441899, China. FAU - Shao, Zhong AU - Shao Z AD - Department of Emergency, Fushun Third Hospital, Fushun, Liaoning Province, 113004, China. FAU - Zhou, Shuang AU - Zhou S AD - Acupuncture and Massage College, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. FAU - Fang, Bang-Jiang AU - Fang BJ AD - Department of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China. fangbji@163.com. AD - Institute of Critical Care, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. fangbji@163.com. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20220504 PL - China TA - Chin J Integr Med JT - Chinese journal of integrative medicine JID - 101181180 RN - 0 (Nucleic Acids) RN - 9007-41-4 (C-Reactive Protein) RN - S88TT14065 (Oxygen) SB - IM MH - C-Reactive Protein MH - China MH - Cough/drug therapy MH - Disease Progression MH - Fatigue MH - Fever MH - Humans MH - *Nucleic Acids MH - Oxygen MH - Retrospective Studies MH - SARS-CoV-2 MH - Treatment Outcome MH - *COVID-19 Drug Treatment PMC - PMC9068500 OTO - NOTNLM OT - Baidu Jieduan Granule OT - COVID-19 OT - common type OT - integrated Chinese and Western medicine EDAT- 2022/05/05 06:00 MHDA- 2022/10/04 06:00 PMCR- 2022/05/05 CRDT- 2022/05/04 23:57 PHST- 2022/02/06 00:00 [accepted] PHST- 2022/05/05 06:00 [pubmed] PHST- 2022/10/04 06:00 [medline] PHST- 2022/05/04 23:57 [entrez] PHST- 2022/05/05 00:00 [pmc-release] AID - 10.1007/s11655-022-3673-x [pii] AID - 3673 [pii] AID - 10.1007/s11655-022-3673-x [doi] PST - ppublish SO - Chin J Integr Med. 2022 Oct;28(10):885-893. doi: 10.1007/s11655-022-3673-x. Epub 2022 May 4.